Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.
Saved in:
| Title: | Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. |
|---|---|
| Authors: | Gbesemete D; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Ramasamy MN; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ibrahim M; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Hill AR; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Raud L; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Ferreira DM; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Guy J; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Dale AP; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Laver JR; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Coutinho T; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Science, University of Southampton, Southampton, UK., Reed TAN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Babbage G; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Weissfeld L; WCG Clinical, Princeton, NJ, USA., Lang W; WCG Clinical, Princeton, NJ, USA., Locht C; Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr., Samal V; ILiAD Biotechnologies, Weston, FL, USA., Goldstein P; ILiAD Biotechnologies, Weston, FL, USA., Solovay K; ILiAD Biotechnologies, Weston, FL, USA., Rubin K; ILiAD Biotechnologies, Weston, FL, USA., Noviello S; ILiAD Biotechnologies, Weston, FL, USA., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. |
| Source: | The Lancet. Microbe [Lancet Microbe] 2025 Dec; Vol. 6 (12), pp. 101211. Date of Electronic Publication: 2025 Dec 01. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41344352 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gbesemete+D%22">Gbesemete D</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Ramasamy+MN%22">Ramasamy MN</searchLink>; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Ibrahim+M%22">Ibrahim M</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Hill+AR%22">Hill AR</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Raud+L%22">Raud L</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Ferreira+DM%22">Ferreira DM</searchLink>; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Guy+J%22">Guy J</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Dale+AP%22">Dale AP</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Laver+JR%22">Laver JR</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Coutinho+T%22">Coutinho T</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Faust+SN%22">Faust SN</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Science, University of Southampton, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Reed+TAN%22">Reed TAN</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Babbage+G%22">Babbage G</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.<br /><searchLink fieldCode="AU" term="%22Weissfeld+L%22">Weissfeld L</searchLink>; WCG Clinical, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lang+W%22">Lang W</searchLink>; WCG Clinical, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Locht+C%22">Locht C</searchLink>; Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr.<br /><searchLink fieldCode="AU" term="%22Samal+V%22">Samal V</searchLink>; ILiAD Biotechnologies, Weston, FL, USA.<br /><searchLink fieldCode="AU" term="%22Goldstein+P%22">Goldstein P</searchLink>; ILiAD Biotechnologies, Weston, FL, USA.<br /><searchLink fieldCode="AU" term="%22Solovay+K%22">Solovay K</searchLink>; ILiAD Biotechnologies, Weston, FL, USA.<br /><searchLink fieldCode="AU" term="%22Rubin+K%22">Rubin K</searchLink>; ILiAD Biotechnologies, Weston, FL, USA.<br /><searchLink fieldCode="AU" term="%22Noviello+S%22">Noviello S</searchLink>; ILiAD Biotechnologies, Weston, FL, USA.<br /><searchLink fieldCode="AU" term="%22Read+RC%22">Read RC</searchLink>; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101769019%22">The Lancet. Microbe</searchLink> [Lancet Microbe] 2025 Dec; Vol. 6 (12), pp. 101211. <i>Date of Electronic Publication: </i>2025 Dec 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101769019 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-5247 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226665247%22">26665247 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Microbe <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41344352 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.lanmic.2025.101211 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101211 Titles: – TitleFull: Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gbesemete D – PersonEntity: Name: NameFull: Ramasamy MN – PersonEntity: Name: NameFull: Ibrahim M – PersonEntity: Name: NameFull: Hill AR – PersonEntity: Name: NameFull: Raud L – PersonEntity: Name: NameFull: Ferreira DM – PersonEntity: Name: NameFull: Guy J – PersonEntity: Name: NameFull: Dale AP – PersonEntity: Name: NameFull: Laver JR – PersonEntity: Name: NameFull: Coutinho T – PersonEntity: Name: NameFull: Faust SN – PersonEntity: Name: NameFull: Reed TAN – PersonEntity: Name: NameFull: Babbage G – PersonEntity: Name: NameFull: Weissfeld L – PersonEntity: Name: NameFull: Lang W – PersonEntity: Name: NameFull: Locht C – PersonEntity: Name: NameFull: Samal V – PersonEntity: Name: NameFull: Goldstein P – PersonEntity: Name: NameFull: Solovay K – PersonEntity: Name: NameFull: Rubin K – PersonEntity: Name: NameFull: Noviello S – PersonEntity: Name: NameFull: Read RC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2025 Dec Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2666-5247 Numbering: – Type: volume Value: 6 – Type: issue Value: 12 Titles: – TitleFull: The Lancet. Microbe Type: main |
| ResultId | 1 |
